Compare Repligen Corporation Common Stock (RGEN) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Health Care Select Sector SPDR Fund — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Health Care Select Sector SPDR Fund trades at $175.94 (market cap $44.49B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 4× Repligen Corporation Common Stock's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| RGEN | XLV | |
|---|---|---|
Market Cap | $11.14B | $44.49B |
Volume | 1,259,263 | 8,745,019 |
Sector | Health | — |
52-Week High | $194.57 | $175.68 |
52-Week Low | $102.87 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XLV trades at $169.66, down 1.35% on the day, while maintaining a bullish technical outlook with strong moving average support. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 60 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and its competitive positioning against peer healthcare ETFs.
The ETF offers defensive growth exposure with healthcare sector stability, though elevated RSI levels suggest near-term consolidation. Political volatility and pharmaceutical trial failures present sector-specific risks, while XLV's technical strength and institutional interest support continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
